Chimerix to Present at the 35th Annual J.P. Morgan Healthcare Conference
January 04 2017 - 8:00AM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company discovering and
developing medicines that improve outcomes for immunocompromised
patients, today announced that M. Michelle Berrey, M.D., M.P.H,
President and Chief Executive Officer of Chimerix, will
present at the 35th Annual J.P. Morgan Healthcare
Conference on Wednesday, January 11,
2017 at 8:30 a.m. PT (11:30 a.m. ET) at
the Westin Saint Francis Hotel in San Francisco, CA.
A live audio webcast of the presentation will be available on
the Investor Relations section of Chimerix’s website at
http://ir.chimerix.com/events.cfm, where it will be archived for
approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to
discovering and developing medicines that improve outcomes for
immunocompromised patients. Chimerix's proprietary lipid
conjugate technology has produced brincidofovir (BCV, CMX001);
CMX157, which was licensed to ContraVir Pharmaceuticals; and
earlier-stage compounds. Chimerix recently announced a new
clinical candidate, CMX521, for the treatment and/or prevention of
norovirus. For further information, please visit Chimerix's
website, www.chimerix.com.
CONTACT:
Investor Relations:
ir@chimerix.com
or
Will O’Connor
Stern Investor Relations
Will@sternir.com
212-362-1200
Media:
Becky Vonsiatsky
W2O Group
bvonsiatsky@w2ogroup.com
413-478-2003
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Apr 2023 to Apr 2024